Role of NAD+, oxidative stress, and tryptophan metabolism in autism spectrum disorders

International Journal of Tryptophan Research

Volumn 6, Issue SUPPL.1, 2013, Pages 15-28

  Essa, Musthafa Mohamed ^a,b   Subash, Selvaraju ^a   Braidy, Nady ^c   Al Adawi, Samir ^a   Lim, Chai K ^b,d   Manivasagam, Tamilarasan ^e   Guillemin, Gilles J ^b,d,f  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e ANNAMALAI UNIVERSITY   (India)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antioxidants; Autism; Mitochondrial dysfunction; NAD; Oxidative stress; Tryptophan

Indexed keywords

EID: 84882700404     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S11355     Document Type: Article

References (170)

1. Kanner L. Autistic psychopathy in childhood. Nervous Child. 1943;2: 217-50.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DMS-IV-TR). Arlington, VA: American Psychiatric Association Publishing, Inc; 2000.
4. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3): 205-23.
5. Kosinovsky B, Hermon S, Yoran-Hegesh R, et al. The yield of laboratory investigations in children with infantile autism. J Neural Transm. 2005; 112(40):587-96.
6. Johnson CP, Myers SM; for American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120(5):1183-215.
7. Brian J, Bryson SE, Garon N, et al. Clinical assessment of autism in high-risk 18-month-olds. Autism. 2008;12(5):433-56.
8. Fournier KA, Hass CJ, Naik SK, Lodha N, Cauraugh JH. Motor coordination in autism spectrum disorders: a synthesis and meta-analysis. J Autism Dev Disord. 2010;40(10):1227-40.
9. Van Waelvelde H, Oostra A, Dewitte G, Van Den Broeck C, Jongmans MJ. Stability of motor problems in young children with or at risk of autism spectrum disorders, ADHD, and or developmental coordination disorder. Dev Med Child Neurol. 2010;52(8):e174-8.
10. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA. Jan 2003;289(1):49-55.
11. Talat A. Nationality study of autism in Saudi Arabia King Abdualaziz City for Science and Technology; 2008.
12. Davidovitch M, Holtzman G, Tirosh E. Autism in the Haifa area-an epidemiological perspective. Isr Med Assoc J. 2001;3(3):188-9.
13. Manning SE, Davin CA, Barfield WD, et al. Early diagnosis of autism spectrum disorders in Massachusetts birth cohorts, 2001-2005. Pediatrics. 2011;127(6):1043-51.
14. Ritvo ER, Jorde LB, Mason-Brothers A, et al. The UCLA-University of Utah epidemiology survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry. 1989;146(8):1032-6.
15. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr. 2005;94(1):2-15.
16. Annual Health Report (2008) Ministry of Health, Sultanate of Oman.
17. Al-Farsi YM, Al-Sharbati MM, Al-Farsi OA, Al-Shafaee MS, Brooks DR, Waly MI. Brief report: Prevalence of autistic spectrum disorders in the Sultanate of Oman. J Autism Dev Disord. 2011;41(6):821-5.
18. Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011;168(9): 1-9.
19. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Investigators; Centers for Disease Control. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States 2002. MMWR Surveill Summ. 2007;56(1): 12-28.
20. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3a lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006;173(1-2):126-34.
21. Kaluzna-Czaplinska J, Grys W, Rynkowski J. Neurotoxic factors in the child's environment as a reason for developmental disorders in autism. Nowa Pediatr. 2008;3:50-7.
22. Cannell JJ. On the aetiology of autism. Acta Paediatr. 2010;99(8): 1128-30.
23. Coleman M, Gillberg C. The Autisms, 4th ed. New York, NY: Oxford University Press; 2011.
24. de Theije CG, Wu J, da Silva SL, et al. Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management. Eur J Pharmacol. 2011;668 Suppl 1:S70-80.
25. Buehler MR. A proposed mechanism for autism: an aberrant neuroimmune response manifested as a psychiatric disorder. Med Hypotheses. 2011;76(6): 863-70.
26. London EA. The environment as an etiologic factor in autism: a new direction for research. Environ Health Perspect. 2000;108 Suppl 3:401-4.
27. Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett. 2005;26(5):439-46.
28. Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A. 2007;70(12):1046-51.
29. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology. 2008;29(1):190-201.
30. White LF. Intestinal pathology in autism. Exp Biol Med (Maywood). 2003; 228(6):639-49.
31. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1(6):352-8.
32. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003;112(5):e420.
33. Bölte S, Poustka F. The relation between general cognitive level and adaptive behavior domains in individual with autism with and without co-morbid mental retardation. Child Psychiatry Hum Dev. 2002;33(2): 165-72.
34. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26(3):383-92.
35. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factor for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005;161(10):916-25.
36. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67-81.
37. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001;120(1-2):170-9.
38. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46(2): 76-84.
39. Molloy CA, Morrow AL, Meinzen-Derr J, et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. 2006;172(1-2): 198-205.
40. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574-9.
41. Dimayuga FO, Wang C, Clark JM, Dimayuga ER, Dimayuga VM, Bruce-Keller AJ. SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells. J Neuroimmunol. 2007;182(1-2):89-99.
42. El-Ansary AK, Ben Bacha AG, Al-Ayadhi LY. Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J Neuroinflammation. 2011;8:142.
43. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem. 2009;42(10-11):1032-40.
44. McGinnis WR. Oxidative stress in autism. Altern Ther Health Med. 2004; 10(6):22-36.
45. Essa MM, Braidy N, Vijayan KR, Subash S, Guillemin GJ. Excitotoxicity in the pathogenesis of autism. Neurotox Res. Epub Oct 13, 2012.
46. Christen Y. Oxidative stress and Alzheimer's disease. Am J Clin Nutr. 2000;71(2):621S-9.
47. Tórsdóttir G, Kristinsson J, Sveinbjörnsdóttir S, Snaedal J, Jóhannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol. 1999;85(5): 239-43.
48. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology. 2000;7(3):153-63.
49. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9(7):684-97.
50. Bilici M, Efe H, Köroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. 2001;64(1): 43-51.
51. Kuloglu M, Atmaca M, Tezcan E, Ustundag B, Bulut S. Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobiology. 2002;46(4):186-9.
52. Kuloglu M, Atmaca M, Tezcan E, Gecici O, Tunckol H, Ustundag B. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology. 2002;46(1):27-32.
53. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
54. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11(6):851-76.
55. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci. 2004;75(21):2539-49.
56. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80(6):1611-7.
57. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem. 2009;42(10-11):1032-40.
58. Essa MM, Guillemin GJ, Waly MI, et al. Increased markers of oxidative stress in autistic children of the Sultanate of Oman. Biol Trace Elem Res. 2012;147(1-3):25-7.
59. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004;254(3):143-7.
60. Lopez-Hurtado E, Prieto JJ. Immunocytochemical analysis of interneurons in the cerebral cortex of autistic patients. Proceedings of the International Meeting for Autism Research; May 7-8, 2004; Sacramento, CA; 2004:153.
61. Ming X, Stein TP, Brimacombe M, Johnson WG, Lamber GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids. 2005;73(5):379-84.
62. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67(5):341-3.
63. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res. 2006;66(4):182-8.
64. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):947-56.
65. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007;70(10):837-51.
66. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res. 2009;34(2):386-93.
67. Sögüt S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003;331(1-2): 111-7.
68. Evans TA, Perry G, Smith MA, et al. Evidence for oxidative damage in the autistic brain, in Autism. In: Chauhan A, Chauhan V, Brown WT, editors. Oxidative Stress, Inflammation and Immune Abnormalities. Boca Raton, FL: Taylor and Francis Group, LLC; 2009:35-46.
69. López-Hurtado E, Prieto JJ. A microscopic study of language-related cortex in autism. American Journal of Biochemistry and Biotechnology. 2008;4(2):130-45.
70. Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J Neuroimmunol. 2010;219(1-2):114-8.
71. Essa MM, Guillemin GJ, Waly MI, et al. Reduced levels of antioxidant proteins in children with autism in Oman. International Journal of Nutrition, Pharmacolology, Neurological Diseases. 2012;2(1):53-6.
72. Boucard AA, Chubykin AA, Comoletti D, Taylor P, Südhof TC. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha-and beta-neurexins. Neuron. 2005;48(2):229-36.
73. Chih B, Gollan L, Scheiffele P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron. 2006;51(2):171-8.
74. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455(7215):903-11.
75. Laumonnier F, Bonnet-Brilhault F, Gomot M, et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet. 2004;74(3):552-7.
76. Yan J, Oliveira G, Coutinho A, et al. Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol Psychiatry. 2005;10(4):329-32.
77. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003;302(5646):826-30.
78. Garber K. Neuroscience. Autism's cause may reside in abnormalities at the synapse. Science. 2007;317(5835):190-1.
79. Baudouin SJ, Gaudias J, Gerharz S, et al. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science. 2012; 338(6103):128-32.
80. Hunter JW, Mullen GP, McManus JR, Heatherly JM, Duke A, Rand JB. Neuroligin-deficient mutants of C. elegans have sensory processing deficits and are hypersensitive to oxidative stress and mercury toxicity. Dis Model Mech. 2010;3(5-6):366-76.
81. Zeviani M, Di Donato S. Mitochondrial disorders. Brain. 2004;127(Pt 10): 2153-72.
82. Graf WD, Marin-Garcia J, Gao H, et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child Neurol. 2000;15(6):357-61.
83. Fillano JJ, Goldenthal MJ, Rhodes CH, Marín-García J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol. 2002;17(6):435-9.
84. Pons R, Andreu AL, Checcarelli N, et al. Mitochondrial DNA abnormalities and autistic spectrum disorders. J Pediatr. 2004;144(1):81-5.
85. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One. 2008;3(11): e3815.
86. Shoffner J, Hyams L, Niedziela-Langley G, et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol. 2010; 25(4):429-34.
87. Álvarez-Iglesias V, Mosquera-Miguel A, Cuscó I, Carracedo1 A, Pérez-Jurado LA, Salas A. Reassessing the role of mitochondrial DNA mutations in autism spectrum disorder. BMC Med Genet. 2011;12:50.
88. Coleman M, Blass JP. Autism and lactic acidosis. J Autism Dev Disord. 1985;15(1):1-8.
89. László A, Horváth E, Eck E, Fekete M. Serum serotonin, lactate and pyruvate levels in infantile autistic children. Clin Chim Acta. 1994;229(1-2): 205-7.
90. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 1999;45(3):287-95.
91. Lombard J. Autism: a mitochondrial disorder? Med Hypotheses. 1998; 50(6):497-500.
92. Chugani DC, Sundram BS, Behen M, Lee ML, Moore GJ. Evidence of altered energy metabolism in autistic children. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(4):635-41.
93. Filipek AP, Juranek J, Smith M, et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol. 2003;53(6): 801-4.
94. Scholte HR. The biochemical basis of mitochondrial diseases. J Bioenerg Biomembr. 1988;20(2):161-91.
95. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol. 2005;47(3):185-9.
96. Correia C, Coutinho AM, Diogo L, et al. Brief report: High frequency of biochemical markers for mitochondrial dysfunction in autism: no association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene. J Autism Dev Disord. 2006;36(8):1137-40.
97. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003;33(1):93-7.
98. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34(6): 615-23.
99. De Meirleir L, Lissens W, Denis R, et al. Pyruvate dehydrogenase deficiency: clinical and biochemical diagnosis. Pediatr Neurol. 1993;9(3): 216-20.
100. Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA. 2010;304(21):2389-96.
101. Haynes V, Traaseth NJ, Elfering S, Fujisawa Y, Giulivi C. Nitration of specific tyrosines in FoF1 ATP synthase and activity loss in aging. Am J Physiol Endocrinol Metab. 2010;298(5):E978-87.
102. Krebs HA. Pyridine nucleotides and rate control. Symp Soc Exp Biol. 1973; 27:299-318.
103. Schapira AH. Human complex I defects in neurodegenerative diseases. Biochim Biophys Acta. 1998;1364(2):261-70.
104. Atwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21(10):1133-45.
105. Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science. 1984;224(4653):1057-63.
106. Pickett J, London E. The neuropathology of autism: a review. J Neuropathol Exp Neurol. 2005;64(11):925-35.
107. Okada M, Ishikawa M, Mizushima Y. Identification of a ubiquitin-and ATP-dependent protein degradation pathway in rat cerebral cortex. Biochim Biophys Acta. 1991;1073(3):514-20.
108. Huganir RL, Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron. 1990;5(5):555-67.
109. Silver IA, Erecinska M. Energetic demands of the Na+/K+ ATPase in mammalian astrocytes. Glia. 1997;21(1):35-45.
110. Gilman AG. G proteins: transducers of receptor-generated signals. Ann Rev Biochem. 1987;56:615-49.
111. Almeida A, Heales SJ, Bolaños JP, Medina JM. Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion. Brain Res. 1998;790(1-2):209-16.
112. Rothenberg SJ, Williams FA Jr, Delrahim S, et al. Blood lead levels in children in south central Los Angeles. Arch Environ Health. 1996;51(5): 383-8.
113. Minshew N, Goldstein G, Dombrowski SM, Panchalingam K, Pettegrew JW. A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry. 1993;33(11-15):762-73.
114. Schifter T, Hoffman JM, Hatten HP Jr, Hanson MW, Coleman RE, DeLong GR. Neuroimaging in infantile autism. J Child Neurol. 1994;9(2): 155-61.
115. László A, Horváth E, Eck E, Fekete M. Serum serotonin, lactate and pyruvate levels in infantile autistic children. Clin Chim Acta. 1994;229(1-2): 205-7.
116. Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, Lev D. Should autistic children be evaluated for mitochondrial disorders? J Child Neurol. 2004;19(5):379-81.
117. Erecinska M, Cherian S, Silver IA. Energy metabolism in mammalian brain during development. Prog Neurobiol. 2004;73(6):397-445.
118. Adams JB, Holloway CE, George F, Quig D. Analyses of toxic metals and essential minerals in the hair of Arizona children with autism and associated conditions, and their mothers. Biol Trace Elem Res. 2006;110(3): 193-209.
119. Ming X, Brimacombe M, Wagner GC. Prevalence of motor impairment in autism spectrum disorders. Brain Dev. 2007;29(9):565-70.
120. + metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12-9.
121. Oliveira G, Ataíde A, Marques C, et al. Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions. Dev Med Child Neurol. 2007;49(10):726-33.
122. Adams JB, Audhya T, McDonough-Means S, et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond). 2011;8(1):34.
123. Gutteridge JMC. The protective action of superoxide dismutase on metal-ion catalysed peroxidation of phospholipids. Biochem Biophys Res Commun. 1977;77(1):379-86.
124. Maddipati KR, Marnett LJ. Characterization of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidase. J Biol Chem. 1987;262(36):17398-403.
125. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21(1):2-14.
126. Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trézéguet V, Lauquin GJ, Brandolin G. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 2003;426(6962):39-44.
127. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009;23(8):2374-83.
128. Masino SA, Kawamura M, Wasser CD, Pomeroy LT, Ruskin DN. Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol. 2009;7(3):257-68.
129. Russell MW, du Manoir S, Collins FS, Brody LC. Cloning of the human NADH: ubiquinone oxidoreductase subunit B13: localization to chromosome 7q32 and identification of a pseudogene on 11p15. Mamm Genome. 1997;8(1):60-1.
130. Marui T, Funatogawa I, Koishi S, et al. The NADH-ubiquinone oxidoreductase 1 alpha subcomplex 5 (NDUFA5) gene variants are associated with autism. Acta Psychiatr Scand. 2011;123(2):118-24.
131. Heguilen RM, Gimenez MI, Imperiali N, Bernasconi A, Algranati SL, Dos Ramos Farias E. Ca2+/Mg2+-ATPase activity in erythrocyte membrane in hypercalciuric nephrolithiasic patients. Nephrology. 2009;7(1):12-7.
132. Ji L, Chauhan A, Brown WT, Chauhan V. Increased activities of Na+/K+-ATPase and Ca2+/Mg2+-ATPase in the frontal cortex and cerebellum of autistic individuals. Life Sci. 2009;85(23-26):788-93.
133. Al-Mosalem OA, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to energy metabolism in Saudi autistic children. Clin Biochem. 2009;42(10-11):949-57.
134. El-Ansary A, Al-Daihan S, Al-Dbass A, Al-Ayadhi L. Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children. Clin Biochem. 2010;43(1-2):63-70.
135. Chauhan A, Gu F, Essa MM, et al. Brain region specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem. 2011;117(2):209-20.
136. Longo N, Ardon O, Vanzo R, Schwartz E, Pasquali M. Disorders of creatine transport and metabolism. Am J Med Genet C Semin Med Genet. 2011;157(1):72-8.
137. Boekema EJ, Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem. 2007;282(1):1-4.
138. Bertram R, Gram Pedersen M, Luciani DS, Sherman A. A simplified model for mitochondrial ATP production. J Theor Biol. 2006;243(4):575-86.
139. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000;29(3-4):222-30.
140. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life. 2001; 52(3-5):159-64.
141. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 2009;34(6):1021-9.
142. Burchell VS, Gandhi S, Deas E, Wood NW, Abramov AY, Plun-Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. Expert Opin Ther Targets. 2010;14(5):497-511.
143. Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta. 2010;1802(1):212-20.
144. Tsao CY, Mendell JR. Autistic disorder in 2 children with mitochondrial disorders. J Child Neurol. 2007;22(9):1121-3.
145. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One. 2008; 3(11):e3815.
146. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-51.
147. Pan W, Kastin AJ. Adipokines and the blood-brain barrier. Peptides. 2007;28(6):1317-30.
148. Fujita-Shimizu A, Suzuki K, Nakamura K, et al. Decreased serum levels of adiponectin in subjects with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):455-8.
149. Essa MM, Al-Sharbati MM, Al-Farsi YM, et al. Reduced levels of adiponectin in Omani autistic children-a brief report. International Journal of Biological and Medical Research. 2011;2(3):793-5.
150. Essa MM, Braidy N, Al-Sharbati MM, et al. Elevated plasma leptin levels in autistic children of Sultanate of Oman. International Journal of Biological and Medical Research. 2011;2(3):803-5.
151. Garrido M, Espino J, Toribio-Delgado AF, et al. A jerte valley cherry-based product as a supply of tryptophan. Int J Tryptophan Res. 2012;5:9-14.
152. Cubero J, Toribio F, Garrido M, et al. Assays of the amino acid tryptophan in cherries by HPLC-fluorescence. Food Analytical Methods. 2010;3(1): 36-9.
153. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2:45-60.
154. Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med (Berl). 2007;85(12):1351-9.
155. D'Eufemia P, Finocchiaro R, Celli M, Viozzi L, Monteleone D, Giardini O. Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism. Biomed Pharmacother. 1995;49(6):288-92.
156. Kaluzna-Czaplinska J, Michalska M, Rynkowski J. Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry. Med Sci Monit. 2010;16(10):CR488-92.
157. Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology. 2001;24(5):467-77.
158. Essa MM, Al-Sharbati MM, Al-Farsi YM, et al. Altered activities of monoamine oxidase A in Omani autistic children-a brief report. International Journal of Biological and Medical Research. 2011;2(3):811-3.
159. Davies NW, Guillemin G, Brew BJ. Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder. Int J Tryptophan Res. 2010;3: 121-40.
160. Kipnis J, Derecki NC, Yang C, Scrable H. Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common? Trends Immunol. 2008;29(10):455-63.
161. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron. 2009;64(1):93-109.
162. McAllister AK, van de Water J. Breaking boundaries in neural-immune interactions. Neuron. 2009;64(1):9-12.
163. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009;204(2):313-21.
164. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17(7):389-94.
165. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16(1):77-86.
166. Braidy N, Grant R, Adams S, Guillemin GJ. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J. 2010;277(2):368-82.
167. Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005;33(3): 195-201.
168. Nabi R, Serajee FJ, Chugani DC, Zhong H, Huq AH. Association of tryptophan 2,3 dioxygenase gene polymorphism with autism. Am J Med Genet B Neuropsychiatr Genet. 2004;125B(1):63-8.
169. Rind HB, Russo AF, Whittemore SR. Developmental regulation of tryptophan hydroxylase messenger RNA expression and enzyme activity in the raphe and its target fields. Neuroscience. 2000;101(3):665-77.
170. Essa MM, Braidy N, Waly MI, et al. Antioxidant Status and Reduced Energy Metabolism in Autistic Children. Res Autism Spectr Disord. 2013;7:557-65